Antisense Oligonucleotides Targeting FXN Intron 1 for FRDA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antisense oligonucleotides targeting the GAA repeat expansion in Friedreich's ataxia (FRDA) patients face challenges in effectively increasing frataxin protein expression while minimizing off-target interactions.
Innovation Solution
Development of antisense oligonucleotides with specific regions of complementarity to intron 1 of the FXN transcript, designed to avoid complementarity to other sites in the human genome, thereby reducing off-target effects and enhancing frataxin expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antisense oligonucleotides target the GAA repeat expansion region, then frataxin expression is restored, but off-target interactions occur
Solution Approach 1:
The patent divides the FXN intron 1 region into specific targetable sequences adjacent to the GAA repeat expansion, selecting regions that are unique to FXN and do not exist elsewhere in the genome. This segmentation allows targeting a specific sub-region rather than the entire GAA repeat area, reducing off-target effects while maintaining therapeutic efficacy.
Solution Approach 2:
The invention applies local quality by designing oligonucleotides that target specific local sequences (immediately adjacent to the GAA repeat) rather than the entire repeat region. This localized targeting ensures high specificity to the FXN gene while avoiding complementarity to other genomic sites, thus minimizing off-target interactions.
2Manufacturing precision
If antisense oligonucleotides are designed to avoid off-target sites, then specificity increases, but design complexity increases
Solution Approach 1:
The patent performs preliminary genome-wide sequence analysis to identify regions in FXN intron 1 that are unique and do not have complementarity to other genomic sites. By pre-screening and selecting optimal target sequences before oligonucleotide synthesis, the design process becomes more systematic and less complex, ensuring high specificity without requiring extensive trial-and-error optimization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed antisense oligonucleotides effectively increase frataxin expression while minimizing off-target interactions, potentially offering a more targeted therapeutic approach for FRDA.
Implementation Method 1
an antisense oligonucleotide comprising a region of complementarity to an intron of a FXN transcript
Data Source
AI summary
The present disclosure provides antisense compounds, methods, and compositions for increasing FXN gene expression. The present disclosure provides antisense compounds, methods, and compositions for the treatment, prevention, or amelioration of diseases, disorders, and conditions associated with FXN in a subject in need thereof. Also contemplated are antisense compounds and methods for the preparation of a medicament for the treatment, prevention, or amelioration of a disease, disorder, or condition associated with FXN.